Catalyst Biosciences Inc (CBIO)


Stock Price Forecast

Oct. 30, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Catalyst Biosciences Inc chart...

About the Company

catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.

CEO

Nassim Usman

Exchange

NASDAQ

$11M

Total Revenue

35

Employees

$19M

Market Capitalization

-6.50

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CBIO News

Catalyst Biosciences Announces Closing of Public Offering of Common Stock

6mon ago, source: ADVFN

Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, (the Company), today announced ...

Milestone Scientific Stock (AMEX:MLSS), Quotes and News Summary

1y ago, source: Benzinga.com

Howmet Aerospace shares fell 0.1% to close at $45.98 on Friday. Gainers Catalyst Biosciences Inc (NASDAQ: CBIO) rose 105% to $0.49 in pre-market trading. South Korea's GC Biopharma said it has ...

Building Connections: Blue Hen Executive Network

2y ago, source: University of Delaware

Grant Blouse, AS93, vice president of Catalyst Biosciences, Inc., enjoyed the interaction with his fellow alumni and appreciated hearing more about how he can become more engaged with his alma mater. ...

Cautious Optimism Amidst Clinical Progress and Regulatory Hurdles for Solid Biosciences

5h ago, source:

Solid Biosciences (SLDB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 15. Analyst ...

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

18d ago, source: Seeking Alpha

Avidity Biosciences, Inc. (NASDAQ:RNA) has a pretty extensive ... Should the data turn out to be positive, then this would be one catalyst that might cause the stock price to trade higher.

Catalyst, Inc.: CATALYST NAMES JENNIFER MCCOLLUM NEXT PRESIDENT & CEO

13d ago, source: Finanznachrichten

alongside the committed Catalyst staff, Board, and Supporters." McCollum most recently served as the CEO of Linkage, Inc., a SHRM company dedicated to advancing women and consistently ranked as a ...

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

18d ago, source: Nasdaq

Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry ... nerve blocks and prepare for the significant catalyst ahead in NOPAIN. In parallel, we are taking ...

11 Best Small Cap Pharma Stocks to Invest In

14d ago, source: Yahoo Finance

We took a look, and some notable picks are Esperion Therapeutics, Inc. (NASDAQ:ESPR), Dynavax Technologies Corporation (NASDAQ:DVAX), and Pacira BioSciences, Inc. (NASDAQ:PCRX). A pharmaceutical ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript

17d ago, source: InvestingChannel on MSN

Q4 2023 Earnings Call Transcript February 29, 2024 Pacira BioSciences, Inc. reports earnings inline with expectations.

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

18d ago, source: Stockhouse

Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its ... in two key lower extremity nerve blocks and prepare for the significant catalyst ahead in ...

Q4 2023 Pacira Biosciences Inc Earnings Call

18d ago, source: Yahoo Finance

Reinhart; CFO; Pacira BioSciences, Inc. Frank D. Lee; CEO & Director ... which will be a solid tailwind for EXPAREL. We have a significant catalyst ahead in NOPAIN and then 2024, will be a key setup ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...